* If you want to update the article please login/register
Autophagy may also give tumors cells that are suffering from chemotherapy or radiation damage. We evaluated the safety, tolerability, and effectiveness of mixing CQ or HCQ with carboplatin and gemcitabine in patients with refractory solid tumors. Methods This single institution phase I dose escalation study was designed to determine the maximum tolerated dose of CQ/HCQ in patients with advanced solid tumors. In each patient dose cohort, a starting dose of CQ or HCQ 50 mg was used in conjunction with standard starting doses of CG and increased in increments of 50 mg. The MTD was discovered to be the CQ/HCQ 100 mg/daily equivalent, as a result of a combination of CG with thrombocytopenia and/or neutropenia dose limitation. Conclusion The MTD Q/HCQ's was lower than previously reported for CQ/HCQ with concomitant use of chemotherapeutic regimens, most likely because of the myelosuppressive nature of CG in newly treated patients.
Source link: https://doi.org/10.3389/fonc.2022.811411
Background: TPS591: Neoadjuvant cisplatin-based combination chemotherapy improves survival in cisplatin-eligible patients with muscle invasive bladder cancer. Neoadjuvant immune checkpoint inhibitors have been found to be safe and effective, although the benefit may not extend to the majority of pts. The combination of GCa and an ICI has been shown to be safe and effective in cisplatin-ineligible metastatic urothelial carcinoma. In the neoadjuvant situation, a combination of GCa and an ICI could have a dramatic effect on a large number of MIUC patients by providing early systemic therapy to pts with cisplatin-ineligible MIUC. Compared to MIUC's upfront surgery, we hypothesized that the combination of GCa and avelumab, a PD-L1 inhibitor, could lead to pathologic complete remissions and long-term outcomes. Methods: The combination of GCa and avelumab as neoadjuvant therapy versuss. upfront surgery for pts with cisplatin-ineligible MIUC including MIBC and high-risk upper tract urothelial carcinoma was tested in this multicenter, randomized, open-label phase II trial is comparing the effectiveness of GCa and avelumab as a neoadjus uts In both arms, the decision to investigate whether or ureterectomy is deferred to investigator discretion. Eligible pts include those from MIBC or high-grade UTUC with a significant urothelial component that is cisplatin-ineligible. The trial will have a chance of 90 percent to show a decrease in the pCR rate from 15% to 35% with 178 evaluable pts. Arm A is a student at the University of Aura, 2000 mg/m2 IV days 1, 8 every 3 weeks x 4 cycles, carboplatin AUC 4. 5 IV day 1 every 3 weeks x 4 cycles, and avelumab 800 mg/m2 IV days 1 every 2 weeks x 6 cycles.
Source link: https://doi.org/10.1200/jco.2022.40.6_suppl.tps591
Purpose Although gemcitabine and carboplatin are a common treatment for patients with advanced urothelial cancer who are ineligible for cisplatin, patients with advanced urothelial cancer are ineligible for cisplatin are ineligible for cisplatin are not, poor outcomes have been uneven. In advanced UC, this trial examined the efficiency and safety of bevacizumab with GCa. Conclusions The predesigned PFS of more than 4. 8 months, which was considered adequate for further investigation, was not reached by a 95 percent one-sided lower confidence bound of 4. 77 months for median PFS. The role of bevacizumab in UC will be determined by an ongoing phase III study in patients who are eligible for therapy with cisplatin.
Source link: https://doi.org/10.1200/jco.2012.42.5215
Abstract Lessons Learned Lessons Learned The biweekly GEM plus CBDCA dose and schedule demonstrated safe results with mild toxicities in elderly patients with advanced NSCLC. The biweekly GEM plus CBDCA supplement to the 3-week NSCLC regimen may be a healthier alternative to the 3-week regimen. Background The gemcitabine-carboplatin combination is widely used for non-small cell lung cancer and elderly patients, but a high incidence of thrombocytopenia has been documented, and the correct dosage and administration times are uncertain. This multicenter phase II study examined the safety and tolerability of GEM-CBDCA for elderly patients with chemotherapy-resistant NSCLC. Patients with chemotherapy-naive clinical status 0–1 and with stage IIIB/IV NSCLC were treated chemotherapy biweekly. The median age of 76 years was 76 years; 35 percent were women; 35 percent were male; and 27 patients had adenocarcinoma; 35 percent were men; and 27 patients had adenocarcinoma. Conclusion This GEM-CBDCA combination administered biweekly demonstrated safe results with minor toxicities in elderly patients with elevated NSCLC.
Source link: https://doi.org/10.1634/theoncologist.2019-0717
A platinum compound combined with a third-generation cytotoxic agent is the most effective therapy for non-small cell lung cancer stages IIIb and IV. We decided to carry out a phase II study to see if the platinum compound could be replaced with pemetrexed with similar results and without an increase in side effects. Patients were randomly assigned to either the standard arm of gemcitabine plus carboplatin or the experimental arm of gemcitabine plus peplatin. Pepexed can use platinum compounds in the first-line treatment of stage IIIb and IV NSCLC without raising the side effects.
Source link: https://doi.org/10.1634/theoncologist.2014-0181
In the first-line treatment of patients with carcinoma of unknown primary site, the purpose and toxicity of the sequential administration of paclitaxel, carboplatin, and oral etoposide were determined by gemcitabine and irinotecan were determined. Fifty-nine patients had well differentiated adenocarcinoma, 73 patients had poorly differentiated carcinoma, and 121 patients had poor achievement status scores of 0 or 1. Both responses were similar in the two key histologic tumor types, but patients with liver-dominant tumors and patients with lymph-node-dominant tumors were poor, while lymph-dominant tumors were less common. Sequential combination chemotherapy with paclitaxel/oral etoposide and gemcitabine/irinotecan is an effective treatment for patients with carcinoma of unknown primary site, but overall toxicities are greater than those seen with other combinations of new drugs and survival in 264 other patients treated in our four previous phase II trials.
Source link: https://doi.org/10.1634/theoncologist.9-6-644
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions